Reported Earlier: Johnson & Johnson Secures Permanent J-Code For INLEXZO, Streamlining Billing For BCG-Unresponsive Bladder Cancer Therapy

Johnson & Johnson has secured a permanent J-Code for its INLEXZO therapy, which is used for treating BCG-unresponsive bladder cancer. This new billing code is expected to streamline the reimbursement process and improve patient access to the treatment. The development signifies a strategic move to enhance the market presence of INLEXZO in the oncology sector.